NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price & News $36.05 +1.38 (+3.98%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$34.56▼$36.0750-Day Range$24.26▼$41.3852-Week Range$23.09▼$48.48Volume942,433 shsAverage Volume1.10 million shsMarket Capitalization$3.85 billionP/E RatioN/ADividend YieldN/APrice Target$57.54 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Arrowhead Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside61.1% Upside$58.08 Price TargetShort InterestBearish5.09% of Float Sold ShortDividend StrengthN/ASustainability-2.55Upright™ Environmental ScoreNews Sentiment0.61Based on 10 Articles This WeekInsider TradingSelling Shares$2.79 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.38) to ($2.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector297th out of 983 stocksPharmaceutical Preparations Industry134th out of 486 stocks 4.3 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $58.08, Arrowhead Pharmaceuticals has a forecasted upside of 61.1% from its current price of $36.05.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.09% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 8.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.Environmental SustainabilityThe Environmental Impact score for Arrowhead Pharmaceuticals is -2.55. Previous Next 2.0 News and Social Media Coverage News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Arrowhead Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,786,309.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions65.46% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($1.38) to ($2.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -25.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -25.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 8.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arrowhead Pharmaceuticals (NASDAQ:ARWR) StockArrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.Read More Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Stock News HeadlinesJune 2, 2023 | msn.comPiper Sandler Maintains Arrowhead Pharmaceuticals (ARWR) Overweight RecommendationJune 1, 2023 | americanbankingnews.comShort Interest in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expands By 8.1%June 2, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 29, 2023 | americanbankingnews.comVaxxinity (NASDAQ:VAXX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) Head-To-Head SurveyMay 27, 2023 | americanbankingnews.comBrokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $59.75May 25, 2023 | markets.businessinsider.comArrowhead Pharmaceuticals (ARWR) Receives a Buy from B.Riley FinancialMay 24, 2023 | msn.comChardan Capital Reiterates Arrowhead Pharmaceuticals (ARWR) Buy RecommendationMay 24, 2023 | markets.businessinsider.comWhere Arrowhead Pharma Stands With AnalystsJune 2, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 23, 2023 | msn.comWhat Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol DisorderMay 23, 2023 | msn.comArrowhead says anti-lipid agent caused up to 48% decline in bad cholesterolMay 19, 2023 | msn.comArrowhead Pharmaceuticals Remains A Buy For Pipeline PotentialMay 19, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Receives New Coverage from Analysts at StockNews.comMay 18, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 5.2%May 16, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for Arrowhead Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:ARWR)May 13, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Lowered to Market Perform at SVB LeerinkMay 12, 2023 | msn.comSVB Leerink Downgrades Arrowhead Pharmaceuticals (ARWR)May 12, 2023 | americanbankingnews.comSVB Securities Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) to Market PerformMay 9, 2023 | americanbankingnews.comFY2023 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Raised by Chardan Capital (NASDAQ:ARWR)May 9, 2023 | americanbankingnews.comArrowhead Pharmaceuticals, Inc. Expected to Earn Q3 2023 Earnings of ($0.71) Per Share (NASDAQ:ARWR)May 7, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Reiterates Rating from 500.comMay 6, 2023 | americanbankingnews.comChristopher Richard Anzalone Sells 54,928 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) StockMay 5, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)May 4, 2023 | msn.comGoldman Sachs Maintains Arrowhead Pharmaceuticals (ARWR) Buy RecommendationMay 4, 2023 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Issues Earnings Results, Beats Expectations By $1.10 EPSMay 3, 2023 | markets.businessinsider.comB.Riley Financial Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)May 3, 2023 | msn.comRBC Capital Reiterates Arrowhead Pharmaceuticals (ARWR) Outperform RecommendationSee More Headlines ARWR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARWR Company Calendar Last Earnings5/02/2023Today6/02/2023Next Earnings (Estimated)8/03/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees329Year FoundedN/APrice Target and Rating Average Stock Price Forecast$58.08 High Stock Price Forecast$90.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+61.0%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-176,060,000.00 Net Margins-53.83% Pretax Margin-54.37% Return on Equity-33.49% Return on Assets-18.21% Debt Debt-to-Equity RatioN/A Current Ratio6.60 Quick Ratio6.60 Sales & Book Value Annual Sales$243.23 million Price / Sales15.71 Cash FlowN/A Price / Cash FlowN/A Book Value$4.35 per share Price / Book8.22Miscellaneous Outstanding Shares106,900,000Free Float101,555,000Market Cap$3.82 billion OptionableOptionable Beta0.99 Key ExecutivesChristopher Richard AnzalonePresident, Chief Executive Officer & DirectorPatrick C. O'brienCOO, Secretary & Chief Compliance OfficerKenneth Allen MyszkowskiChief Financial OfficerJavier San MartinChief Medical OfficerPeter CarignanVice President-Clinical OperationsKey CompetitorsUltragenyx PharmaceuticalNASDAQ:RAREBlueprint MedicinesNASDAQ:BPMCProthenaNASDAQ:PRTACytokineticsNASDAQ:CYTKReata PharmaceuticalsNASDAQ:RETAView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 4,077 shares on 5/26/2023Ownership: 0.024%Capital Impact Advisors LLCSold 11,435 shares on 5/23/2023Ownership: 0.014%Ameriprise Financial Inc.Sold 39,357 shares on 5/22/2023Ownership: 0.436%Putnam Investments LLCSold 2,122 shares on 5/22/2023Ownership: 0.047%JPMorgan Chase & Co.Bought 89,143 shares on 5/18/2023Ownership: 2.722%View All Insider TransactionsView All Institutional Transactions ARWR Stock - Frequently Asked Questions Should I buy or sell Arrowhead Pharmaceuticals stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARWR shares. View ARWR analyst ratings or view top-rated stocks. What is Arrowhead Pharmaceuticals' stock price forecast for 2023? 13 Wall Street research analysts have issued 1-year target prices for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $27.00 to $90.00. On average, they anticipate the company's share price to reach $58.08 in the next twelve months. This suggests a possible upside of 62.5% from the stock's current price. View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts. How have ARWR shares performed in 2023? Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of the year. Since then, ARWR stock has decreased by 11.9% and is now trading at $35.74. View the best growth stocks for 2023 here. Are investors shorting Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 5,230,000 shares, an increase of 8.1% from the April 30th total of 4,840,000 shares. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is currently 4.5 days. Approximately 5.1% of the shares of the company are sold short. View Arrowhead Pharmaceuticals' Short Interest. When is Arrowhead Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our ARWR earnings forecast. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings data on Tuesday, May, 2nd. The biotechnology company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $1.10. The biotechnology company earned $146.27 million during the quarter, compared to analysts' expectations of $45.48 million. Arrowhead Pharmaceuticals had a negative net margin of 53.83% and a negative trailing twelve-month return on equity of 33.49%. The firm's quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.41 earnings per share. What ETFs hold Arrowhead Pharmaceuticals' stock? ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Direxion mRNA ETF (MSGR), ALPS Medical Breakthroughs ETF (SBIO), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Biotech ETF (XBI), Neuberger Berman Disrupters ETF (NBDS), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD). What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (11.89%), State Street Corp (5.52%), JPMorgan Chase & Co. (2.72%), Geode Capital Management LLC (1.94%), Credit Suisse AG (1.30%) and FMR LLC (1.28%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Patrick O'brien and William D Waddill. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $35.74. How much money does Arrowhead Pharmaceuticals make? Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $3.82 billion and generates $243.23 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. How many employees does Arrowhead Pharmaceuticals have? The company employs 329 workers across the globe. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401. This page (NASDAQ:ARWR) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.